Director Julie T. Kunkel buys 1,000 BLMN shares at $6.46 amid -44.9% year-to-date decline; stock down -17.8% in 30 days.
Director Julie T. Kunkel purchased 1,000 shares at $6.46 on 2026-03-05, increasing her holdings by 19.7% to 6,065 shares. The stock is trading at $5.81, down from a 52-week high of $10.54 (a -44.9% decline) and has fallen -17.8% over the prior 30 days. Kunkel's prior three trades at BLMN show mixed timing outcomes: one buy appreciated 13.5% by the 90-day mark, but a second buy subsequently declined -22.4%, suggesting discretionary judgment has been inconsistent at this ticker. Fundamental context is concerning: the company generated $928.8M in quarterly revenue but reported a net loss of $-45.9M, with minimal annual revenue growth of +0.1%, though the low P/E of 6.32 may reflect distressed pricing rather than opportunity.
Director Kunkel buys 1,500 shares at $6.37 amid -61.3% decline from 52-week high; unprofitable company and poor insider track record.
Kunkel Julie T. purchased 1,500 shares at $6.37 on 2025-11-11, increasing her holdings by 42.1% from 3,565 to 5,065 shares. The transaction occurs as the stock trades at $6.49, substantially below the 52-week high of $16.78 (-61.3%), and follows a 10.6% decline over both the 30-day and 90-day periods. Notably, the company reported negative net income of $-45.9M on quarterly revenue of $928.8M and contracted 15.4% year-over-year, indicating fundamental operational stress. Kunkel's prior purchase at this ticker on 2025-02-28 fell 25.4% over 30 days and 22.4% over 90 days, establishing a pattern of poorly timed entry points; across her broader trading history, 0 of 2 prior buys achieved positive 90-day returns. This purchase offers no clear conviction signal—it appears driven by depressed valuation in a deteriorating business rather than by management confidence in recovery.
Director Kunkel buys 1,500 shares of BLMN at $9.94; stock now $8.24, down -72.3% from 52-week high.
Julie T. Kunkel, a Director, purchased 1,500 shares at $9.94 on 2025-02-28, increasing her holdings by 72.6% from 2,065 to 3,565 shares. The transaction occurred as BLMN trades 72.3% below its 52-week high of $29.72 and has declined 34.4% over 30 days and 36.2% over 90 days, signaling sustained weakness. Kunkel's cross-ticker buy track record shows 1 prior purchase averaging 2.8% return in 30 days but -3.2% over 90 days with a 0% win rate, and her single prior trade at BLMN (August 2024 buy) exhibited the same -3.2% 90-day outcome with 0 of 1 prior buys well-timed. Fundamental conditions remain stressed: the company faces -15.4% annual revenue contraction and was unprofitable over its most recent full fiscal year, with latest quarter net income at $6.9M against $1.0B revenue.
Director Kunkel Julie T. purchases 1,000 BLMN shares at $15.65, doubling holdings to 2,000 shares as stock down -45.2% from 52-week high.
Director Kunkel Julie T. acquired 1,000 shares of Bloomin' Brands at $15.65 on 2024-08-12, bringing total holdings from 1,000 to 2,000 shares (a +100.0% increase in position size). The acquisition occurred at a price substantially below the 52-week high of $29.72, with the stock trading -45.2% from that peak and -9.0% over the prior 30 days. The company maintains a low P/E of 5.74 with positive fundamentals including $1.1B quarterly revenue and $28.4M net income. This purchase by a director during a period of significant stock weakness, combined with doubled personal ownership, may indicate insider conviction at current valuations, though the recent 90-day decline of -32.2% and modest transaction size warrant observation of broader insider activity patterns to establish confidence in directional intent.
